What is GeneDx Holdings's SG&A?

GeneDx Holdings (WGS) reported SG&A of $74.59M in Q1 2026.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

GeneDx Holdings WGS SG&A

SG&A at other companies

Natera, Inc.NTRA

$327.94M+22.9%

Tempus AI, Inc.TEM

$212.59M+37.5%

Bio-Rad LaboratoriesBIO

$212.4M+1.7%

Quest DiagnosticsDGX

$504M+5.9%

RevvityRVTY

$253.88M+1.7%

Labcorp HoldingsLH

$551M+0.9%

Other financials

Income statement

See full

Revenue$102.3M+17.4%

Gross profit$68.2M+16.6%

Operating income-$57.5M-1,163%

Net income-$63.3M-870%

EPS (diluted)-$2.16-839%

Balance sheet

See full

Cash & equivalents$94.9M-5.7%

Total debt$96.7M+82.5%

Total equity$254.1M-1.3%

Total assets$506.3M+13.4%

Cash flow

See full

Operating cash flow-$32.4M-418%

CapEx$6.5M+5.3%

Free cash flow-$38.9M-1,059%

Valuation

See full

Market cap$1.89B-24.3%

Profitability

See full

Gross margin69.6%+4.3pp

Operating margin-14.9%—

Net margin-17.6%—

FCF margin3.8%+2.1pp

Returns & leverage

See full

Return on equity-30.4%—

Debt / equity0.4×+0.2×

Current ratio3.1×-0.2×

Where this comes from

Reported directly by GeneDx Holdings in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: GeneDx Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about GeneDx Holdings's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is GeneDx Holdings's SG&A?: GeneDx Holdings (WGS) reported SG&A of $74.59M in Q1 2026.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.